Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
116 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Pipeline Review, H2 2017 Summary Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Histone deacetylase 2 is an enzyme encoded by the HDAC2 gene. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It forms transcriptional repressor complexes by associating with MAD, SIN3, YY1 and N-COR. It interacts in the late S-phase of DNA-replication with DNMT1 in the other transcriptional repressor complex composed of DNMT1, DMAP1, PCNA, and CAF1. It deacetylates TSHZ3 and regulates its transcriptional repressor activity. Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) pipeline Target constitutes close to 24 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 1, 11 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Dermatology, Gastrointestinal, Immunology, Infectious Disease, Musculoskeletal Disorders and Respiratory which include indications Breast Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Follicular Lymphoma, Melanoma, Myelodysplastic Syndrome, Neuroblastoma, Non-Small Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Colon Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Essential Thrombocythemia, Lung Cancer, Mantle Cell Lymphoma, Neurodegenerative Diseases, Neurology, Non-Hodgkin Lymphoma, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sickle Cell Disease, Solid Tumor, Thalassemia, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Adenoid Cystic Carcinoma (ACC), Alopecia, Alzheimer's Disease, Anaplastic Thyroid Cancer, Asthma, Becker Muscular Dystrophy, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Bone Disorders, Burkitt Lymphoma, Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), CNS Lymphoma, Cognitive Disorders, Colorectal Cancer, Depression, Duchenne Muscular Dystrophy, Gallbladder Cancer, Glioma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Human Immunodeficiency Virus (HIV) Infections (AIDS), Liver Cancer, Liver Fibrosis, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Renal Cell Carcinoma, Multiple Myeloma (Kahler Disease), Myelofibrosis, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Cancer, Papillary Thyroid Cancer, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Psychiatric Disorders, Recurrent Glioblastoma Multiforme (GBM), Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Systemic Lupus Erythematosus, T-Cell Leukemia and Thyroid Cancer. The latest report Histone Deacetylase 2 - Pipeline Review, H2 2017, outlays comprehensive information on the Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - The report reviews Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects - The report assesses Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Overview 8 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Therapeutics Development 9 Products under Development by Stage of Development 9 Products under Development by Therapy Area 10 Products under Development by Indication 11 Products under Development by Companies 16 Products under Development by Universities/Institutes 23 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Therapeutics Assessment 25 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Companies Involved in Therapeutics Development 31 4SC AG 31 Celgene Corp 31 Chipscreen Biosciences Ltd 32 Curis Inc 33 HitGen LTD 34 Italfarmaco SpA 34 Medivir AB 35 MEI Pharma Inc 35 Merck & Co Inc 36 Sigma-Tau SpA 37 Yungjin Pharm Co Ltd 37 Zhejiang Hisun Pharmaceutical Co Ltd 38 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Drug Profiles 39 4SC-202 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 ACY-1035 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 ACY-1071 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 ACY-738 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 ACY-957 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 CS-3158 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 CUDC-907 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 givinostat - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 HG-3001 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 largazole - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 pracinostat - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 RCY-1305 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 RCY-1497 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 RCY-1992 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 remetinostat - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 resminostat - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 Small Molecule to Inhibit HDAC2 for Oncology - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 Small Molecules to Inhibit HDAC2 for Neurological Disorders - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 ST-3595 - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 tucidinostat - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 vorinostat - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 YPL-001 - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Dormant Products 99 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Discontinued Products 102 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Product Development Milestones 103 Featured News & Press Releases 103 Aug 02, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 103 Jul 19, 2017: Regenacy Pharmaceuticals Presents Data Demonstrating that HDAC1,2 Inhibition Improved Cognitive Function in Mouse Models of Alzheimer's Disease at the Alzheimer's Association International Conference 104 Jun 14, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome 104 Jun 05, 2017: Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 105 May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting 106 May 18, 2017: Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 107 Apr 19, 2017: GNTbm to begin Phase III clinical trial in Taiwan of epigenetic regulator Chidamide for late-stage breast cancer 107 Apr 11, 2017: New mechanistic insights into 4SC-202's epigenetic mode of action 108 Apr 07, 2017: Medivir announces positive data from the phase II study of remetinostat in patients with early-stage cutaneous T-cell lymphoma 109 Jan 24, 2017: Overall survival benefit for resminostat in first-line liver cancer study subgroup 110 Jan 11, 2017: Regenacy Pharma's HDAC1 Inhibitor ACY-957 Demonstrates Potent Anti-Leukemic Activities 110 Jan 11, 2017: Regenacy Pharma's HDAC2 Inhibitor ACY-1035 Demonstrates Potent Anti-Leukemic Activities 111 Dec 16, 2016: First patient enrolled in pivotal RESMAIN study of resminostat in CTCL 112 Dec 05, 2016: Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 112 Dec 04, 2016: Acetylon Presents Preclinical Data Demonstrating the Utility of Selective HDAC1,2 Inhibition by ACY-957 to Induce Gamma Globin (HBG) Protein Expression for the Treatment of Sickle Cell Disease and Beta-Thalassemia 113 Appendix 115 Methodology 115 Coverage 115 Secondary Research 115 Primary Research 115 Expert Panel Validation 115 Contact Us 115 Disclaimer 116
List of Tables
Number of Products under Development by Stage of Development, H2 2017 9 Number of Products under Development by Therapy Areas, H2 2017 10 Number of Products under Development by Indications, H2 2017 11 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13 Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 14 Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017 15 Number of Products under Development by Companies, H2 2017 16 Products under Development by Companies, H2 2017 17 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 18 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 19 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 20 Products under Development by Companies, H2 2017 (Contd..4), H2 2017 21 Products under Development by Companies, H2 2017 (Contd..5), H2 2017 22 Number of Products under Investigation by Universities/Institutes, H2 2017 23 Products under Investigation by Universities/Institutes, H2 2017 24 Number of Products by Stage and Mechanism of Actions, H2 2017 26 Number of Products by Stage and Route of Administration, H2 2017 28 Number of Products by Stage and Molecule Type, H2 2017 30 Pipeline by 4SC AG, H2 2017 31 Pipeline by Celgene Corp, H2 2017 32 Pipeline by Chipscreen Biosciences Ltd, H2 2017 33 Pipeline by Curis Inc, H2 2017 34 Pipeline by HitGen LTD, H2 2017 34 Pipeline by Italfarmaco SpA, H2 2017 35 Pipeline by Medivir AB, H2 2017 35 Pipeline by MEI Pharma Inc, H2 2017 36 Pipeline by Merck & Co Inc, H2 2017 37 Pipeline by Sigma-Tau SpA, H2 2017 37 Pipeline by Yungjin Pharm Co Ltd, H2 2017 38 Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2017 38 Dormant Products, H2 2017 99 Dormant Products, H2 2017 (Contd..1), H2 2017 100 Dormant Products, H2 2017 (Contd..2), H2 2017 101 Discontinued Products, H2 2017 102
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
